At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 32 enrolled
Drug / intervention
AD109 dose1- A +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Randomized Double-Blind Placebo-Controlled 3-Period Single-Dose Crossover Study to Evaluate the Safety and Efficacy of Two Doses of AD-109 in Mild to Moderate Obstructive Sleep Apnea
In Brief
A Phase 2 clinical trial evaluating AD109 dose1- A, AD109 dose2- B, and 1 other intervention for Obstructive Sleep Apnea. Completed, enrolled 32 participants across 3 sites.
Detailed Summary
This is a randomized, 3-period, placebo-controlled, crossover, phase 2 clinical study to examine the efficacy and safety of 2 doses of AD109 vs placebo in patients with mild obstructive sleep apnea.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObstructive Sleep Apnea
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedNov 2020
Enrollment StartDec 2020
Primary CompletionMay 2021
TodayJul 2026
First PostedNov 17, 2020
Enrollment StartDec 22, 2020
Primary CompletionMay 31, 2021
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 5.6 years ago
Interventions
AD109 dose1- Adrug
Oral administration at bedtime
AD109 dose2- Bdrug
Oral administration at bedtime
Placebo- Cdrug
Oral administration at bedtime